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Mesencephalic Astrocyte-Derived 
neurotrophic factor is Upregulated 
with therapeutic fasting in Humans 
and Diet fat Withdrawal in obese 
Mice
emilia Galli1, Jari Rossi2, thomas neumann3,4, Jaan-olle Andressoo  1,5,6, Stefan Drinda7,8 & 
päivi Lindholm1
Dietary restriction induces beneficial metabolic changes and prevents age-related deterioration. 
Mesencephalic astrocyte-derived neurotrophic factor (MANF) shows protective effects on cells in 
various models of degenerative diseases. Here we studied whether circulating concentrations of 
MANF are associated with fasting-induced positive effects. We quantified the levels of circulating 
MANF from 40 human subjects before and after therapeutic fasting. As measured by an enzyme-
linked immunosorbent assay (eLiSA), the mean concentration of plasma MAnf increased after an 
average fasting of 15 days. Plasma MANF levels correlated inversely with adiponectin, a hormone that 
regulates metabolism, thus suggesting that MANF levels are related to metabolic homeostasis. To 
study the effects of dietary intervention on MANF concentrations in mice, we developed an ELISA for 
mouse MANF and verified its specificity using MANF knock-out (KO) tissue. A switch from high-fat to 
normal diet increased MAnf levels and downregulated the expression of unfolded protein response 
(UPR) genes in the liver, indicating decreased endoplasmic reticulum (ER) stress. Liver MANF and 
serum adiponectin concentrations correlated inversely in mice. Our findings demonstrate that MANF 
expression and secretion increases with dietary intervention. The MANF correlation to adiponectin and 
its possible involvement in metabolic regulation and overall health warrants further studies.
Fasting is the voluntary restriction of food intake for a defined period and can be therapeutically used for dif-
ferent indications1. Medically supervised dietary restriction (i.e., nutritional intake of 200–500 kcal/day for a 
period of few weeks) has been successfully used for improving conditions such as metabolic syndrome2. Short- to 
mid-term fasting therapy has been reported to decrease body mass index (BMI), glucose and insulin levels, and 
insulin resistance in overweight and obese subjects3. Fasting regulates secretion of adiponectin and leptin, which 
are hormone-like peptides derived from adipose tissue and maintain metabolic homeostasis4. Increased levels 
of circulating adiponectin have been reported in dietary restriction studies5. In general, fasting regimes induce 
adaptive programs to reduce metabolism in response to food deprivation, promote health, and extend lifespan in 
multiple model organisms6,7.
MANF (also known as ARMET) was originally identified based on its survival-promoting activity on cultured 
brain dopamine neurons8. Since then, the protective properties of MANF on various cell types have been demon-
strated in animal models of Parkinson’s disease, cerebral ischemia, spinocerebellar ataxia, myocardial infarction, 
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and retinal degeneration9–14. Manf conventional knock-out mice develop insulin-dependent diabetes due to post-
natal loss of pancreatic insulin-producing beta cell mass, indicating that MANF is important for the function and 
maintenance of pancreatic beta cells15. Circulating MANF levels are increased in human children with recent 
onset of type 1 diabetes and in adults with prediabetes and type 2 diabetes16,17, suggesting that alterations in levels 
of circulating MANF can indicate changes in energy metabolism.
Subcellular MANF localizes to the ER and ER stress has been shown to induce MANF expression and secretion 
in vitro and in vivo18–26. Proliferation and survival of pancreatic beta cells in Manf−/− mice were evidently com-
promised due to chronic ER stress, suggesting that MANF is important for the maintenance of ER homeostasis in 
the cells15. ER stress is caused by an imbalance between protein synthesis and protein folding capacity. To restore 
ER homeostasis, an adaptive unfolded protein response (UPR) is induced by the activation of inositol-requiring 
enzyme (IRE)1, PKR-like ER kinase (PERK), and activating transcription factor (ATF)6 pathways27,28. Obesity 
and nutrient excess are known to induce chronic ER stress in the liver and several other tissues29.
In a recently published study, systemic MANF was shown to have anti-aging properties related to the regu-
lation of metabolism and immune response30. Using heterochronic parabiosis, which connects the blood circu-
lation from young and old mice, the authors demonstrated that the presence of MANF in the young blood was 
required for the rejuvenating effect of parabiosis on age-related liver degeneration in old mice. Similarly, systemic 
delivery of recombinant MANF protein was able to alleviate age-related liver damage in mice30.
Here, we aimed to determine whether dietary restriction, a known health-promoting and anti-aging regime, 
affects circulating concentrations of MANF in humans. We measured plasma MANF concentrations before and 
after therapeutic fasting using in-lab human MANF ELISA16 and studied the correlations between MANF levels 
and biochemical and physiological parameters. To perform dietary intervention in mice, diet-induced obese 
(DIO) mice were subjected to dietary fat withdrawal by changing from a high-fat diet (HFD) to a normal diet 
(ND). We decided to use DIO mice to model the present human study population, since 75% of the human sub-
jects in our study were overweight or obese. Changes in circulating and tissue levels of MANF and expression of 
UPR markers were studied in relation to diet change and subsequent weight loss in the mice. Since human MANF 
ELISA does not recognize mouse MANF16, a novel ELISA for mouse MANF protein was produced, and the spec-
ificity of the ELISA was confirmed using serum and tissue samples from MANF KO mice15.
Results
Plasma MANF is increased in fasting humans. The study population consisted of 40 adults with an 
average age of 54.5 ± 12.5 years (range 22–77 years) who volunteered to fast for therapeutic effects on various 
health conditions (Table 1). The average concentration of MANF in human plasma samples before fasting was 
6.1 ± 2.3 ng/ml (median: 5.8 ng/ml; range: 2.6–14.0 ng/ml, Fig. 1a). In samples collected after fasting, the average 
MANF concentration was 7.5 ± 3.0 ng/ml (median: 7.1 ng/ml; range: 3.2–16.8 ng/ml). The mean MANF plasma 
concentration increased by 1.4 ng/ml (+23%) during fasting (p < 0.001) (Fig. 1a,b). The MANF concentration in 
plasma increased in 72.5% (n = 29/40) of the study subjects with an average increase of 2.3 ± 2.0 ng/ml (range: 
0.2–11.0 ng/ml, +44%) from pre-fasting MANF concentration (Fig. 1b). In cases of decreased plasma MANF 
levels (n = 9/40, 22.5%), the average decrease was −1.2 ± 1.0 ng/ml (range: −0.1 to −3.6 ng/ml, −17%). MANF 
concentration was unchanged in two samples (5%).
The average duration of fasting was 15.3 ± 6.3 days (range 9–49 days, Table 1). We found no correlation 
between time of fasting and MANF concentration (ng/ml) after fasting (rs = −0.16, p = 0.34, n = 40), or the per-
centage change in MANF during of fasting (rs = 0.07, p = 0.66, n = 40; data not shown).
Correlation analysis of circulating MANF with BMI, glucose, and insulin. MANF serum levels did 
not differ between lean (BMI < 25 kg/m2), overweight (BMI 25–29.9 kg/m2), or obese (BMI ≥ 30 kg/m2) subjects 
in pre- or post-fasting situations. The percentage change in MANF during fasting also did not differ between the 
different BMI groups (p > 0.05; data not shown). Circulating MANF concentrations showed no correlation with 
weight, BMI, waist circumference, or with blood lipids (Table 2). Furthermore, no correlations were observed 
between MANF and blood glucose or insulin levels, or with the levels measured after oral glucose tolerance test 
General
Age, years (mean ± SD, range) 54.5 ± 12.5, 22–77
Female, n (%) 30 (75%)
Days of fasting (mean ± SD, range) 15.3 ± 6.3, 9–49
BMI (kg/m2), (mean ± SD, range) 29.8 ± 8.6, 19–61
Diagnoses
Overweight, BMI 25–29.9 kg/m2, n (%) 16 (40%)
Obese, BMI ≥ 30 kg/m2, n (%) 14 (35%)
Arthritis (other than rheumatoid arthritis) 8 (20%)
Hypertonia 4 (10%)
Burn out/depression 4 (10%)
Hypothyreosis/struma 3 (7.5%)
History of cancer 3 (7.5%)
Table 1. Selected background information of the human study group. Only the most commonly occurred 
diagnoses are listed. BMI, body mass index.
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(OGTT). No correlation was found between MANF levels and homeostatic model assessment (HOMA) indexes 
for the estimation of insulin resistance (IR) and beta cell function (%β) (HOMA2 IR or HOMA2%β, respectively).
Pre-fasting MANF and adiponectin show an inverse correlation. We found an inverse correlation 
between MANF and adiponectin concentrations measured in pre-fasting plasma samples (rs = −0.36, p = 0.04, 
n = 32, Fig. 1c). Furthermore, the percentage change in MANF concentrations during fasting correlated inversely 
with the percentage change in adiponectin levels (rs = −0.49, p = 0.01, n = 32, Fig. 1d). In contrast to plasma 
MANF, average adiponectin levels measured before and after fasting (9.4 ± 5.7 μg/ml and 10.5 ± 4.9 μg/ml, 
respectively) did not significantly differ. Plasma adiponectin concentration was increased in 59.4% (n = 19/32) 
and decreased in 40.6% (n = 13/32) of the study subjects (p = 0.15; Fig. 1e,f). No correlations were found between 
the plasma levels of MANF and leptin or insulin like-growth factor-1 (IGF-1) (Table 2).
Figure 1. Plasma MANF levels increase with therapeutic fasting in humans. (a) MANF concentrations in 
human plasma samples by ELISA. (b) MANF concentration increased in 72.5% (n = 29/40) of cases after 
fasting (red lines). In 22.5% (n = 9/40) of cases, MANF decreased (blue lines) and in two cases (5%) remained 
unchanged (green lines). (c) Circulating concentrations of MANF (ng/ml) and adiponectin (μg/ml) correlated 
inversely before fasting (rs = −0.36, p = 0.04, n = 32). (d) Percentage change in plasma MANF and adiponectin 
levels between pre- and post-fasting samples correlated inversely (rs = −0.49, p = 0.01, n = 32). (e) Plasma 
adiponectin concentrations before and after fasting by ELISA. (f) Adiponectin concentration increased in 59.4% 
(n = 19/32) and decreased in 40.6% (n = 13/32) of cases after fasting (red and blue lines, respectively). Statistical 
significance was analysed by Wilcoxon signed ranks test in (b,f). Correlations were analysed by Spearman’s rank 
correlation in (c,d). n.s. = not significant.
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Generation and validation of mouse MANF ELISA. To quantify endogenous MANF protein levels in 
mouse serum and tissues, we developed a mouse (m)MANF ELISA and tested its specificity by MANF KO mouse 
samples15. The sensitivity of the mouse MANF ELISA was 29 pg/ml. The assay detected both mouse and human 
MANF but did not detect homologous human cerebral dopamine neurotrophic factor (CDNF) with 59% amino 
acid identity31 and did not respond to MANF KO mouse serum or tissue lysates in contrast to samples from 
wild-type mice (Supplementary Table S1). The mMANF ELISA yielded a slightly different concentration-response 
curve for recombinant mouse (rm) and human (rh) MANF proteins (Supplementary Table S1). The endoge-
nous MANF concentration in mouse serum samples was calculated by the standard curve of rmMANF protein 
whereas endogenous mouse MANF in tissue lysates was calculated by the standard curve of rhMANF. This was 
because mouse tissue samples only gave acceptable dilutional linearity when compared to the rhMANF standard 
curve (Supplementary Table S2).
Recombinant mMANF could be measured with acceptable accuracy and precision (total error within 15%) 
at concentrations of 31.25 to 1000 pg/ml. The average intra- and interassay variations were 5.1% coefficient of 
variation (CV) (range: 3.7–7.5%) and 9.7% CV (range: 5.4–16.5%), respectively (Supplementary Table S3). The 
dynamic range of the mMANF ELISA for rhMANF was 62.5 to 1,000 pg/ml and the average intra- and interas-
say variations were 9.8% CV (range: 7.5–13.0%) and 8.6% CV (range: 4.7–13.4%), respectively (Supplementary 
Table S3). The linearity of dilution was within 80% to 106% in mouse serum samples (n = 7) and 90% to 112% in 
mouse tissue lysates (n = 5) (Supplementary Table S4). The average recovery of 50 to 250 pg/ml spikes of recom-
binant mMANF and hMANF to study samples was 96 ± 8% in mouse sera (n = 18) and 99 ± 5% in tissue lysates, 
respectively (n = 6, Supplementary Table S5).
We found that mouse MANF serum concentrations measured using mouse MANF ELISA correlated posi-
tively with the absorbance values at 414 nm (Abs414nm), signifying the extent of haemolysis in the serum samples 
(rs = 0.86, p < 0.001, n = 90, Supplementary Fig. S1a). By excluding mouse serum samples with Abs414nm ≥ 0.3, 
the positive correlation between MANF concentrations and Abs414nm was abolished (rs = 0.23, p = 0.16, n = 39, 
Supplementary Fig. S1b), indicating that low levels of haemolysis do not dictate serum MANF concentration 
values. Therefore, only the MANF values that were quantified from mouse cardiac serum samples with a cut-off 
limit of 0.3 for Abs414nm we included in the analysis.
Variable
Pre-fasting Post-fasting % change
n
Spearman’s 
Rho p-value n
Spearman’s 
Rho p-value n
Spearman’s 
Rho p-value
Age 40 −0.11 0.52 40 −0.13 0.43 n.a. n.a.
Weight 40 0.04 0.80 40 −0.08 0.65 40 −0.20 0.22
BMI 40 0.02 0.93 40 −0.03 0.87 40 −0.21 0.19
Waist circumference 39 0.09 0.59 29 0.09 0.65 29 −0.12 0.54
Fasting glucose 40 −0.27 0.09 40 −0.05 0.75 40 0.25 0.13
Glucose 0.5 h after OGTT 40 −0.16 0.32 40 0.01 0.94 40 0.02 0.89
Glucose 2 h after OGTT 40 −0.05 0.75 39 0.14 0.39 39 0.07 0.67
Fasting insulin 40 −0.03 0.88 40 0.01 0.97 40 0.14 0.39
Insulin 0.5 h after OGTT 39 0.07 0.66 40 −0.16 0.32 39 −0.17 0.31
First-phase insulin secretion 39 0.07 0.66 40 −0.10 0.56 39 −0.04 0.82
Early insulin response 39 0.10 0.56 40 −0.03 0.85 39 0.03 0.88
Oral disposition index 39 0.09 0.60 40 0.01 0.96 39 0.004 0.98
Matsudata index 39 0.04 0.82 40 0.09 0.60 39 −0.09 0.59
QUICKI 40 −0.05 0.78 40 0.19 0.24 40 −0.19 0.24
HOMA2 IR 40 −0.03 0.86 40 0.04 0.80 39 0.23 0.16
HOMA2%β 40 0.18 0.27 40 0.12 0.45 39 −0.08 0.63
Cholesterol 40 −0.20 0.22 39 −0.11 0.51 39 −0.10 0.55
LDL 40 −0.20 0.23 39 −0.12 0.48 39 −0.18 0.28
HDL 40 −0.15 0.36 39 −0.06 0.73 39 −0.07 0.66
Triglycerides 40 0.04 0.83 39 0.02 0.89 39 0.08 0.61
CRP 40 0.27 0.10 39 −0.03 0.86 38 0.08 0.61
Leukocytes 40 0.22 0.17 40 −0.04 0.79 39 −0.22 0.17
Leptin 33 0.03 0.88 33 −0.11 0.54 33 0.21 0.25
Adiponectin 32 −0.36 0.04* 33 −0.18 0.33 32 −0.49 0.01*
IGF-1 33 0.06 0.75 33 0.04 0.84 33 0.10 0.57
Table 2. Correlation analysis between circulating MANF levels and clinical variables. BMI, body mass index; 
CRP, C-reactive protein; HDL, high-density lipoprotein; HOMA2 IR, Homeostatic model assessment index 
2 insulin resistance; HOMA2%β, Homeostatic model assessment index 2 beta cell function; IGF-1, insulin-
like growth factor 1; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; QUICKI, quantitative 
insulin-sensitivity check index; n.a., not applicable. % change; correlation of the percentage change in MANF 
concentration during fasting with the percentage change in other variables.
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MAnf protein levels are increased in the liver after change from high-fat to normal diet and 
weight loss in mice. To further investigate the changes of MANF levels in relation to diet change in a mam-
malian model system, we analysed MANF concentrations in serum samples from mice on diets with different 
fat content. A group of DIO mice was fed a HFD until 13 weeks-of-age and then switched to a ND for 2 weeks 
(HFD/ND), while a parallel group remained on the HFD. A control group of mice was fed a ND throughout the 
experiment (n = 12/group).
The average weight of the ND, HFD, and HFD/ND groups differed over time as analysed using repeated meas-
ures ANOVA (F(2,33) = 19.7, p < 0.001). Follow-up pairwise comparisons of the interaction with Bonferroni 
correction revealed that the mean weight in the HFD and HFD/ND groups fed a HFD was higher than in the 
ND group at the ages of 10 to 13 weeks (p < 0.001, Fig. 2a). After the change from HFD to ND, the mean weight 
of HFD/ND group was significantly lower than that of the HFD group (p < 0.001) and similar to that of the ND 
group (p = 1.0) as measured at the age of 14 and 15 weeks (Fig. 2a).
The MANF serum concentration in the ND group at 15 weeks-of-age was 3.86 ± 1.09 ng/ml (range: 2.32–
5.85 ng/ml, n = 10). In the HFD group, the MANF concentration was 2.84 ± 0.57 ng/ml (range: 2.11–3.82 ng/ml, 
n = 6), while in the HDF/ND group the corresponding concentration was 4.44 ± 1.76 ng/ml (range: 1.36–6.82 ng/
ml, n = 12, Fig. 2b). The average concentration of serum MANF was 1.62 ng/ml (i.e., 58%) higher in the HFD/ND 
group than the HFD group. The differences in MANF concentrations between the ND, HFD, and HFD/ND 
groups did not reach statistical significance (p = 0.076). Serum MANF concentration in the HFD/ND group did 
not correlate with weight (r = 0.24, p = 0.46, n = 12, data not shown) as measured at 15 weeks-of-age.
To study the effects of diet change on MANF levels in tissues which are important for systemic energy home-
ostasis4, we quantified MANF concentrations in the liver, skeletal muscle, and pancreas of the mice. MANF 
Figure 2. MANF concentration increases in mouse liver after change from high-fat to normal diet. (a) Average 
body weight was higher in mice on high fat diet (HFD and HDF/ND groups) than controls on a normal diet 
(p < 0.001, weeks 10–13). After change from a HFD to a ND, the HFD/ND group lost weight when compared 
with the HFD group (p < 0.001, weeks 14 and 15). The average weight of the HFD/ND group decreased 
similarly as the ND group (p = 1.0, weeks 14 and 15). (b) Serum MANF levels did not differ between the 
study groups as measured by ELISA. (c) MANF concentration increased in the liver of the HFD/ND group 
compared to the HFD or ND groups (p = 0.001 for both). (d) Serum MANF (ng/ml) and liver MANF (ng/mg 
total protein) correlated positively (r = 0.61, p = 0.037, n = 12) in the HFD/ND group. Statistical significance 
was analysed by repeated measures ANOVA followed by pairwise comparisons with Bonferroni correction in 
(a). Differences between group means were analysed by one-way ANOVA followed by Tukey HSD test in (b,c). 
Correlation was analysed by Pearson’s correlation in (d). n.s. = not significant; HFD, high-fat diet; ND, normal 
diet.
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levels did not differ between the ND, HFD, or HFD/ND study groups in the pancreas or skeletal muscle (data 
not shown). However, the mean MANF concentration increased by 72% in the livers of mice from the HFD/
ND group (p = 0.001, Fig. 2c). The liver MANF concentration in the ND and HFD group was 78.7 ± 7.7 and 
79.5 ± 34.5 ng/mg total protein, respectively, while in the HFD/ND group the corresponding concentration was 
136.4 ± 46.8 ng/mg total protein (p = 0.001, n = 12 in all, Fig. 2c). We observed that liver and serum MANF lev-
els correlated positively in the HFD/ND group (r = 0.61, p = 0.037, n = 12, Fig. 2d) but not in the ND (r = 0.28, 
p = 0.43, n = 10, data not shown) or HFD group (r = 0.29, p = 0.57, n = 6, data not shown).
Inverse correlation between liver MANF and serum adiponectin in mice. Serum MANF and adi-
ponectin levels did not correlate statistically significantly in the mice of the HFD/ND group (r = −0.53, p = 0.09, 
n = 11, Fig. 3a). However, we found a strong inverse correlation between circulating adiponectin and liver MANF 
protein concentrations (r = −0.84, p = 0.001, n = 11, Fig. 3b).
Liver MANF concentrations are associated with changes in UPR markers. We next analysed the 
transcript levels of UPR-related genes in liver samples from the ND, HFD, and HFD/ND groups to determine if 
the observed increase in liver MANF levels of the HFD/ND group was related to ongoing ER stress. In the liver 
samples of the obese HFD group, transcript levels of Atf6a, spliced X-box-binding protein 1 (sXbp1), activat-
ing transcription factor 4 (Atf4), DNA damage-inducible transcript 3 (Ddit3, also known as Chop), and DnaJ 
homolog subfamily B member 9 (Dnajb9, also known as Erdj4) were increased compared to the ND group, sug-
gesting that the three UPR sensors ATF6α, IRE1α, and PERK were activated. Activated ATF6α translocates to the 
Golgi where it is cleaved to produce a transcription factor that induces expression of UPR target genes, including 
chaperones and a pro-apoptotic transcription factor Chop32,33. sXbp1, generated downstream of IRE1α, induces 
expression chaperones and components of ER associated degradation (e.g. Erdj419). ATF4, downstream of PERK, 
regulates induction of Chop34.
The diet change from HFD to ND led to a decrease in Atf6α, Chop, and Erdj4 levels in the liver, implying atten-
uation of UPR during the 2 weeks of fat withdrawal. In contrast, the mean transcript levels of Manf (p = 0.003), 
Grp78 (p = 0.039), and total Xbp1 (tXBP1) (p < 0.001) were increased in the HFD/ND group compared to the ND 
group (Fig. 4a). The levels of sXbp1 (p = 0.006) remained high after the diet change in the HFD/ND group when 
compared with the ND group.
Manf transcript and protein levels correlated positively in the livers of the HFD/ND group (r = 0.79, p = 0.002, 
n = 12, Fig. 4b). Furthermore, Manf levels correlated positively with those of Grp78 (r = 0.94, p < 0.001, n = 12, 
Fig. 4c) in the HFD/ND group. Similarly, a positive correlation between liver Manf and Grp78 was found in the 
ND (r = 0.72, p = 0.009, n = 12, data not shown) and HFD (r = 0.83, p = 0.001, n = 12, data not shown) groups.
Discussion
Dietary restriction regimes have been shown to optimize energy metabolism, prevent diseases, and promote 
healthy aging6,7. Recent research suggests that MANF is protective against age-related metabolic diseases as sys-
temic MANF has been shown to relieve metabolic stress and age-related damage in mouse liver30. Another recent 
study suggested that MANF can regulate energy homeostasis, as transgenic overexpression of MANF in the brain 
hypothalamus led to overfeeding and obesity in mice35. In light of these new findings, and together with previous 
studies that have shown protective effects of MANF in animal models of neurodegenerative diseases9,12–14, we first 
aimed to determine if MANF is also induced upon health-promoting dietary restriction in humans. We exam-
ined the effects of therapeutic fasting on concentrations of circulating MANF and analysed correlations between 
MANF and clinical variables to reveal possible mechanisms related to the regulation of circulating MANF levels.
Figure 3. Concentrations of circulating adiponectin and liver MANF correlate inversely in mice after diet 
change. (a) Trend of inverse correlation between serum MANF and adiponectin concentrations (r = −0.53, 
p = 0.09, n = 11) in the HFD/ND group. (b) Inverse correlation between liver MANF and circulating 
adiponectin levels (r = −0.84, p = 0.001, n = 11) in the HFD/ND group. Correlation was analysed by Pearson’s 
correlation in (a,b). HFD, high-fat diet; ND, normal diet.
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We observed that circulating MANF concentrations increased on average by 23% after therapeutic fasting in 
the human study group. Plasma MANF concentrations did not correlate with fasting glucose or fasting insulin, 
before or after dietary restriction, suggesting that circulating MANF levels are not directly linked to glucose 
homeostasis. In a previous study, circulating MANF levels were found to associate with insulin resistance in 
prediabetic type 2 diabetes subjects17. Similar to previous results from subjects with normal glucose tolerance, we 
observed no correlation between circulating MANF and insulin sensitivity indexes.
Interestingly, we found that plasma MANF levels and adiponectin measured before therapeutic fasting showed 
an inverse correlation in humans. Furthermore, the percentage change in MANF and adiponectin levels corre-
lated inversely after fasting. In contrast to adiponectin, plasma MANF levels did not correlate with that of leptin or 
IGF-1, two other energy-metabolism regulating hormones36,37. Increased circulating concentrations of adiponec-
tin are generally related to beneficial metabolic effects, such as improved insulin sensitivity and decreased levels of 
obesity and insulin resistance4. Although adiponectin levels did not change significantly after therapeutic fasting 
in the current human study group, an increased concentration of adiponectin has been reported after very low 
calorie diet38. The negative correlation between MANF and adiponectin levels observed in the human study pop-
ulation were also observed in mice. A trend towards a negative correlation between MANF and adiponectin was 
observed in mouse serum, and a clear negative association was detected between MANF protein concentrations 
in the liver and serum adiponectin. Adiponectin regulates glucose and lipid metabolism in the liver by suppress-
ing glucose production and stimulating fatty acid oxidation39. Since systemic MANF likely regulates liver metab-
olism30, a possible connection between adiponectin and MANF signalling in the liver requires further studies.
To create a mouse model system, we subjected 13-week-old DIO mice to diet change from HFD to nor-
mal chow, thus withdrawing fat from the diet, and generated MANF knock-out tissue-verified ELISA for mouse 
MANF detection. After the diet switch, mouse weights reverted to normal within one week. In similar mouse 
studies, the weight reversal has been slightly slower. For example, diet change from HFD to low fat diet or normal 
chow of 16–17-week-old mice led to weight reversal within two weeks time40,41. Our mice were slightly younger at 
the time of diet switch, which may have affected the speed of weight loss. Variations in diet composition between 
different studies may also contribute to the time scale of weight reversal.
Figure 4. Expression of Manf and UPR genes in livers of mice after diet change as measured by qRT-PCR. (a) 
Expression of Erdj4, Atf6α, and Chop was downregulated by diet fat removal and weight loss in the HFD/ND 
group compared to the HFD group. (b) MANF protein and mRNA levels correlated positively in the HFD/ND 
group (r = 0.79, p = 0.02, n = 12). (c) Manf and Grp78 mRNA levels correlated positively (r = 0.94, p < 0.001, 
n = 12) in the HFD/ND group. Statistical significance was analysed by one-way ANOVA followed by Tukey 
HSD test in (a). Correlation was analysed by Pearson’s correlation in (b,c). HFD, high-fat diet; ND, normal diet.
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Following the change from a HFD to a ND, the average MANF concentration increased by 58% in serum and 
by 72% in the liver compared the HFD group. We found a positive correlation between liver and serum MANF 
concentrations in the HFD/ND group, suggesting that a proportion of circulating MANF originates from liver 
(the major source of plasma proteins) after diet change. In another study, a luciferase reporter construct, designed 
based on the functional properties of the ER retrieval sequence of MANF, was used for monitoring calcium 
depletion related to ER stress. The reporter showed increased secretion from the liver to plasma of rats during ad 
libitum HFD for 3 weeks, whereas caloric restricted HFD normalized the reporter levels indicating restoration of 
ER calcium balance in the liver42. In our study, serum MANF levels were unchanged in mice after HFD of 9 weeks. 
It is possible that the observed increase in reporter levels42 are due to short-term HFD. If so, circulating MANF 
might act during early adaption to metabolic changes. Serum MANF levels in our mice could have increased 
briefly during the development of weight gain and reverted to “normal” levels during the experiment. In the 
study by Sousa-Victor et al. plasma MANF levels were decreased in mice after 12 weeks of ad libitum HFD30. In 
future experiments, it would be informative to study the time course of MANF levels during HFD and diet inter-
vention in order to better understand the regulation of circulating MANF. Furthermore, to investigate whether 
the observed increase in mouse MANF levels after diet change is caused by fat withdrawal or rather by energy 
restriction, it would be informative to measure MANF levels in mice subjected to caloric restricted HFD or ND.
Obesity and nutrient excess are linked to activated UPR in the liver of both humans and mice43,44. Since the 
expression of MANF is increased in ER-stress related disease models in vivo22–25, we investigated whether MANF 
expression in the liver was associated with ER stress and analysed the expression of UPR genes in the ND, HFD, 
and HFD/ND groups. Accordingly, our data show that UPR pathways via IRE1α, ATF6, and PERK sensors are 
activated in the livers of DIO mice on a HFD. Despite the activated UPR, liver Manf mRNA and protein levels 
were not significantly increased in the HFD group compared with the ND group. In future studies, additional 
experimental time points could reveal whether MANF levels are increased briefly during the adaptation to HFD.
After diet change from HFD to ND, mice weight decreased back to normal and levels of Atf6a, Chop, and Erdj4 
were significantly downregulated, indicating decreased ER stress in the liver. However, sXbp1 levels remained 
high, suggesting active IRE1α signalling after dietary switch. It has been shown that hepatic IRE1α can function 
as a metabolic regulator activated by food deprivation45. After diet change, Manf mRNA levels were significantly 
upregulated in the HFD/ND group compared to the ND group. Since the transcription factors sXBP1 and ATF6α 
are known to induce MANF expression19,20,46, it is possible that MANF, downstream of IRE1α, is necessary for 
metabolic adaptations related to the diet change in the liver.
MANF is known to interact with glucose regulated protein 78 (GRP78, also known as BiP), which is a major 
ER chaperone that regulates the activation of UPR sensors10,28. A recent study suggested that MANF mechanis-
tically stabilises GRP78 interaction with client proteins47. Accordingly, we observed a strong positive correlation 
between Manf and Grp78 expression suggesting that changes in Manf expression can be related to the regulation 
of protein homeostasis and UPR. Ablation of MANF expression renders cells vulnerable to ER stress-induced cell 
death18,24,48, whereas overexpression of MANF18 or extracellularly applied MANF26,49,50 can attenuate ER stress 
and protect cells against ER stress-induced apoptosis in vitro. It remains to be studied whether the observed 
increase in MANF expression mediates the attenuation of ER stress and UPR signalling along with diet change 
in the mouse liver.
In summary, increased levels of MANF were observed after therapeutic fasting in humans and after diet inter-
vention in obese mice, suggesting that endogenous MANF may be involved in promoting organismal health. 
Further studies will elucidate whether this knowledge can be used to design novel therapies. More specifically, it 
would be interesting to determine if the observed changes in MANF concentrations are directly related to changes 
in UPR activity, or if MANF is involved in metabolic regulation, possibly in connection to adiponectin.
Methods
Study population and intervention. Characteristics of the study population are presented in Table 1. The 
exclusion criteria included age <18 years, known type 1 or type 2 diabetes or pathologic OGTT, anorexia nervosa, 
underweight (BMI < 18.5 kg/m2), psychological disorders, malignancy, autoimmune diseases, and pregnancy. 
Overall, 40% (n = 16/40) of the population was overweight (BMI 25–29.9 kg/m2), and 35% (n = 14/40) was obese 
(BMI ≥ 30 kg/m2).
The intervention of therapeutic fasting was started with one preparation day, followed by on average 15.3 ± 6.3 
days (range 9–49 days) of fasting. The number of fasting days was adjusted to individual goals and tolerance. 
During fasting, the participants received 300 to 400 kcal/day in the form of vegetable soup, fruit juice, and 20 g of 
honey. The fasting period was followed by at least 3 re-feeding days of progressive caloric intake. The criteria for 
discontinuation of fasting were any adverse advents, systolic blood pressure <90 mm Hg or diastolic <60 mm Hg, 
heart rate at rest >90 bpm, or subjective weakness.
Blood samples were collected before and after the fasting period. Pre-fasting samples were collected on the day 
before the first fasting day or on the first fasting day, and post-fasting samples on the last day of fasting. The blood 
samples were analysed for glucose, insulin, lipids, C-reactive protein (CRP), leukocytes, leptin, adiponectin, and 
IGF-1 levels. Additional samples were collected 0.5 h and 2 h after OGTT and analysed for glucose and insulin 
levels. For estimation of insulin resistance (IR) and beta cell function (%β), HOMA2 IR and HOMA2%β indexes 
were calculated with a non-linear HOMA-algorithm (Software Version 2.2.2. HOMA Calculator, University of 
Oxford). Overall changes in the parameters during fasting will be reported elsewhere (Drinda S., et al., manu-
script under preparation).
The study was approved by the ethics commission of the medical council Baden-Württemberg (Germany) 
and is listed in the German register of clinical trials (DRKS-ID: DRKS00004249, date of registration 31/07/2012). 
The methods used were in accordance with relevant guidelines and regulations. All participants provided written 
informed consent.
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Mice and treatment. All animal experiments using mice were approved by the Finnish Animal Ethics 
Committee of the State Provincial Office of Southern Finland (licenses ESAVI/6005/04.10.03/2012 and 
ESAVI/10564/04.10.07/2014). All methods were carried out in accordance with the relevant guidelines and reg-
ulations. The mice were housed in a 12-h dark/light cycle and had ad libitum access to food and water. To study 
the effect of dietary intervention on MANF levels, mice were subjected to diet change from a HFD to a ND, thus 
reducing fat intake. Seven-week old DIO male C57BL/6J mice were acquired from Jackson Laboratories where 
the mice had been placed on a HFD at 6 weeks of age. The mice continued on a HFD (60% fat, 824054 RM AFE 
(M), Special Diet Services) until the age of 13 weeks. The mice then either remained on a HFD (n = 12) or were 
switched to a ND (4% fat, Teklad Global) (n = 12). A control group of mice (n = 12) received a ND only. Blood 
samples were collected from the saphenous vein at the age of 13 and 15 weeks. The mice were sacrificed at the 
age of 15 weeks and terminal blood was collected by cardiac puncture. Blood samples were left to coagulate for 
30 min at room temperature and centrifuged at 3400 rpm for 10 min in tubes containing separation gel for serum 
collection. Liver, gastrocnemius muscle, and pancreas were dissected and snap frozen in liquid nitrogen. The sera 
and tissues were stored at −80 °C until analysis.
MANF knockout mouse sera and tissues used for the validation of mMANF ELISA were derived from con-
ventional MANF KO mice, which were generated by breeding of Manf+/− heterozygous mice. MANF (Manf_D06, 
C57BL/6N-Manf tm1a(KOMP)Wtsi) targeted embryonic stem cell clones were originally obtained from the KOMP 
Repository (http://www.komp.org)15.
Tissue lysates. Tissues were ground by a Bessman Tissue Pulverizer (Spectrum™) precooled in liquid nitro-
gen. A part of the tissue crush was homogenised by plastic pestles in ice-cold lysis buffer [137 mM NaCl, 20 mM 
Tris-HCl, pH 8.2, 2.5 mM EDTA, 1% NP40, 10% glycerol, 0.5 mM Na3VO4, and Complete Mini protease inhibitor 
cocktail (Roche)] added as 100 μl per 10 mg of the tissue. The lysates were incubated on ice for 20 min, after which 
they were centrifuged at 12 000 rpm for 20 min at 4 °C. The supernatants were then collected and stored at −80 °C 
until analysis.
Quantitative real-time PCR. Total tissue RNA was extracted from a maximum of 30 mg liver crush by 
a NucleoSpin® RNA (Macherey-Nagel) kit according to the manufacturer’s instructions. One microgram of 
DNase-treated RNA was reverse transcribed into cDNA by Maxima H minus RT (Thermo Fischer). 2.5 μl of 
cDNA was used in a qPCR reaction with a LightCycler® 480 SYBR Green I Master run in a LightCycler® 480 
Real-Time PCR System (Roche). The primer sequences employed in this study are listed in Supplementary 
Table S6. Expression levels were calculated according to the primer efficiency values obtained from standard 
curves run on the same plate with samples51. Gene expression levels were normalised to the levels of β-actin 
analysed on the same plate.
Human MANF ELISA. The development and validation of in-lab ELISA for the measurement of MANF 
in human blood has been described earlier16. Briefly, the human MANF sandwich ELISA is built on goat 
anti-human MANF coating antibody (AF3748, R&D Systems), and horseradish peroxidase (HRP)-conjugated 
mouse anti-human MANF detection antibody (4E12, Icosagen). The dynamic range of human MANF ELISA is 
62.5–2000 pg/ml, and its sensitivity is 45 pg/ml. For the quantitation of human MANF in plasma, samples were 
diluted 1:20 and incubated with 0.5 mg/ml Immunoglobulin Inhibiting Reagent (Seralab) for 1 h on ice before 
adding them to the pre-coated ELISA plate.
Mouse MANF ELISA. As the human MANF ELISA16 does not cross-react with mouse MANF, an ELISA 
was developed for the quantitation of mouse MANF in serum and tissues. Briefly, a 96-well plate (MaxiSorp, 
Nunc) was coated with goat anti-human MANF (AF3748, R&D Systems) antibody at a concentration of 2 μg/ml 
in 50 mM carbonate coating buffer (pH 9.6). After overnight incubation at 4 °C, the coated wells were washed 
with buffer (PBS/0.05% Tween) and blocked with 1% casein in PBS/0.05% Tween. Mouse sera were diluted 1:40 
in blocking buffer and applied to the ELISA plate in duplicate, along with standard curve samples of recombinant 
mouse MANF (CYT-827, ProSpec) ranging from 31.25 to 1 000 pg/ml. MANF in mouse tissue lysate samples 
were quantified against the standard curve prepared from recombinant human MANF ranging from 62.5 to 1 
000 pg/ml (P-101–100, Icosagen). The samples and standards were incubated over night at 4 °C. The next day, the 
wells were washed and rabbit anti-MANF (LS-B2688, LSBio) diluted in blocking buffer at 0.5 μg/ml was added to 
the wells and incubated for 3 h at 37 °C followed by incubation with a secondary HRP-linked donkey anti-rabbit 
antibody (NA9340V, GE Healthcare, 1:2000) for 2 h at room temperature. Bound HRP-linked antibody was meas-
ured by adding substrate (3,3′,5,5′-tetramethylbenzidine, DuoSet ELISA Development System, R&D Systems) 
and measuring the absorbance at 450 nm and 540 nm for wavelength correction.
The assay specificity, sensitivity, dynamic range, accuracy (% Relative Error, % RE = derived concentration/
expected concentration × 100%) and precision [% CV, % CV = standard deviation (SD)/mean x 100%] were 
determined as described52. The sensitivity of the mouse MANF ELISA was determined by the mean response 
of 10 blank samples added with three standard deviations and calculating the value from the standard curve. 
Intra-assay variation was determined by measuring three samples of varying MANF concentration in replicates of 
10 from different parts of a plate. Interassay precision was determined by running two different samples in dupli-
cate on six independent assays. The specificity of the ELISA was tested by measuring cross-reactivity to mouse 
serum and tissue lysates from Manf knockout mice15 and to human recombinant CDNF (Icosagen). Linearity of 
dilution and recovery of spiked MANF in the study samples were analysed.
Detection of haemolysis. Haemolysis in mouse sera was found to affect the results analysed by mMANF 
ELISA. Haemolysis in sera was analysed by absorbance at 414 nm53. All samples with Abs414nm ≥ 0.3 were 
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excluded from the analysis. MANF concentrations in human plasma samples as measured by human MANF 
ELISA showed no correlation with absorbance readings at 414 nm (data not shown). Overall, human samples 
gave very low absorbance values at 414nm (on average 0.09 ± 0.04), suggesting low or no presence of haemolysis.
Mouse adiponectin. Adiponectin in mouse serum was quantified by Mouse Adiponectin/Acrp30 
Quantikine ELISA Kit (MRP300, R&D Systems) according to the manufacturer’s instructions.
Statistical analysis. Data are presented as mean ± SD. Shapiro-Wilk test was used to determine normality 
of distribution. Circulating MANF in humans showed a non-normal distribution, thus non-parametric tests 
were applied. Wilcoxon signed-ranks test was used to compare MANF levels in the paired samples taken before 
and after fasting. Correlation of MANF with different parameters was evaluated by Spearman’s rank correlation. 
In mouse samples, MANF and other parameters showed a normal distribution and parametric tests were thus 
applied. Differences in MANF levels between study groups were studied by one-way ANOVA followed by Tukey 
HSD post-hoc test and correlations by Pearson’s r. p-value < 0.05 was considered statistically significant. Statistical 
analysis was performed with SPSS 21.0.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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